Health
FDA Grants Accelerated Approval to GSK's Nelkarmi for Previously Treated ALK-Positive Lung Cancer
The approval gives patients whose cancer outlasted ALK drugs — targeted pills that block a tumor-driving protein — a new option beyond chemotherapy.
The FDA granted accelerated approval Tuesday to neladalkib, sold as Nelkarmi, for adults with ALK-positive lung cancer that progressed after earlier targeted therapy.
The Food and Drug Administration (FDA) announced the accelerated approval on Tuesday, November 17, 2026. Its notice names Nuvalent, Inc. as the applicant of record for neladalkib, sold as Nelkarmi.
ALK is short for anaplastic lymphoma kinase. In this cancer, an abnormal form of the ALK protein drives tumor growth, and targeted drugs block it.
Who the approval covers
The approval covers adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC). Their cancer was already treated in the setting where it could not be removed by surgery.
Patients qualify after one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib. They also qualify after two or more prior ALK TKIs plus platinum-based chemotherapy.
A TKI blocks a kinase, an enzyme tumors use to grow; neladalkib is itself a kinase inhibitor taken by mouth.
The recommended dose is 150 mg orally once daily, with or without food. Patients take it until the disease progresses or side effects become unacceptable.
What the ALKOVE-1 trial showed
Efficacy was evaluated in ALKOVE-1 (NCT05384626), a multicenter, single-arm, open-label, multi-cohort trial. The major outcomes were confirmed overall response rate (ORR) and duration of response (DOR).
ORR is the share of patients whose tumors shrank on treatment. Responses were judged under RECIST v1.1 by blinded independent central review.
In the cohort treated with one prior alectinib (N=67), the ORR was 49%, with a 95% confidence interval of 37% to 62%. Among responders, 76% kept responding for at least six months and 52% for at least 12 months.
In the cohort with two or more prior ALK TKIs and platinum chemotherapy (N=155), the ORR was 32%. Its 95% confidence interval ran from 24% to 40%; 69% of responders reached six months and 51% reached 12 months.
Reuters reported the trial behind the application shrank tumors, including tumors that had spread to the brain. That brain point is Reuters' description of the trial, not a finding in the FDA notice.
Safety and the review path
The label warns of hepatotoxicity, or liver injury, and of renal toxicity, ocular toxicity and creatine phosphokinase elevation. It also warns of embryo-fetal toxicity.
The most common adverse reactions, each in at least 20% of patients, included hepatotoxicity and musculoskeletal pain. Constipation, dysgeusia — a distorted sense of taste — peripheral neuropathy, edema and fatigue were also on that list.
The FDA said the review used the Assessment Aid, a voluntary applicant submission that streamlines assessment. The application received priority review, and neladalkib holds breakthrough therapy and orphan drug designations.
Full prescribing information will be posted on Drugs@FDA; it was not yet posted when the notice appeared Tuesday.
The GSK deal behind the drug
Reuters framed the approval as another regulatory win after GSK's historic $10.6 billion acquisition of Nuvalent. The deal was completed in July, and GSK now owns the company the FDA names as applicant.
Neladalkib was one of two late-stage lung cancer drugs GSK gained in the acquisition. The other, Jideytro, won FDA approval the same month, in July.
Chief Executive Luke Miels is spearheading GSK's return to oncology, a business it exited a decade ago, and Reuters called the Nuvalent deal its most aggressive move in that return.
Reuters said the approval offers a new option for patients who have exhausted existing targeted treatments, for whom chemotherapy has often been the main remaining choice.
The drug will compete with Roche's Alecensa, the most commonly used first-line treatment, and Pfizer's Lorbrena. Both rival drugs also target ALK.
Neladalkib is also being studied against Alecensa in a late-stage trial as a potential first-line treatment. The American Cancer Society expects about 229,410 US lung cancer diagnoses in 2026, Reuters reported.
What remains unknown
Neither source discloses a price or launch timing for Nelkarmi, so the cost to patients and payers is unanswered.
Accelerated approval rests on early evidence such as tumor response. Continued approval conventionally depends on confirmatory evidence, and neither source names a confirmatory trial or deadline.
Whether it works as a first-line treatment is unproven; the late-stage comparison against Alecensa has not reported results.
The decisions that come next
What to watch: the posting of the full prescribing information on Drugs@FDA, carrying the complete label detail.
GSK's launch and pricing disclosures will show how the company positions Nelkarmi against Alecensa and Lorbrena.
The first-line trial against Alecensa is the longer test: success would move neladalkib earlier in treatment, failure would leave it a later-line option.
Sources & evidence
Source checked2 sources · 11 figures
Figure receipts
Sources
Sources used for this piece.
As of Tuesday, Nov. 17, 2026.

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

